{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-024024","form_type":"8-K/A","ticker":"XOMA","cik":"0000791908","company_name":"XOMA Royalty Corp","filed_at":"2025-02-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.358323+00:00","generated_at":"2026-05-26T23:39:53.570056+00:00","sec_items":["9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"XOMA files Pulmokine financials for $20M cash acquisition closed Nov 26, 2024","bullets":["XOMA acquired Pulmokine for $20M cash at closing; historical audited and unaudited financials filed.","Pulmokine 2023 revenue $10M (milestone) and net income $7.95M; cash $708K at year-end.","Pro forma condensed combined balance sheet and income statements filed as Exhibit 99.4.","Pulmokine is a biopharma developing inhaled PDGFR inhibitor for pulmonary arterial hypertension.","Exhibits include audited FY2023, unaudited 9M2024 financials, and independent auditor consent."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-024024","json":"https://secwatch.observer/filing/0001193125-25-024024.json","markdown":"https://secwatch.observer/filing/0001193125-25-024024.md","text":"https://secwatch.observer/filing/0001193125-25-024024.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/791908/000119312525024024/0001193125-25-024024-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/791908/000119312525024024/d935049d8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T23:39:53.570056+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}